MOBI · XBRL financial data
Mobia Medical financial statements, every quarter
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Revenue | 12,074 | 13,505 |
| Revenue from contracts with customers | 12,074 | 13,505 |
| Cost of goods and services sold | 2,133 | 2,267 |
| Gross profit | 9,941 | 11,238 |
| Research and development | 1,692 | 2,278 |
| Selling, general and administrative | 25,186 | 26,886 |
| Total operating expenses | 26,878 | 29,164 |
| Operating income (loss) | (16,937) | (17,926) |
| Interest expense | 357 | 254 |
| Other income (expense) | 282 | 1,281 |
| Income tax expense (benefit) | 0 | 2 |
| Net income (loss) | (17,740) | (21,043) |
| Earnings per share, basic USD per share | (19.30) | (1.10) |
| Earnings per share, diluted USD per share | (19.30) | (1.10) |
| Weighted average shares, basic thousands of shares | 919 | 19,089 |
| Weighted average shares, diluted thousands of shares | 919 | 19,089 |
Balance sheet
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Cash and cash equivalents | 55,725 | 177,090 |
| Accounts receivable | 4,854 | 5,664 |
| Inventory | 6,049 | 6,949 |
| Total current assets | 71,714 | 192,149 |
| Property and equipment, net | 738 | 2,060 |
| Right-of-use asset | 1,001 | 932 |
| Total assets | 73,596 | 195,284 |
| Accounts payable | 3,033 | 2,359 |
| Total current liabilities | 11,834 | 14,472 |
| Lease liability, non-current | 870 | 790 |
| Total liabilities | 61,571 | 22,675 |
| Accumulated deficit | (175,529) | (196,572) |
| Total stockholders' equity | (167,748) | 172,609 |
| Total liabilities and equity | 73,596 | 195,284 |
| Common shares outstanding (cover page) thousands of shares | 33,249 | 33,291 |
Cash flows
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Net income (loss) | (17,740) | (21,043) |
| Stock-based compensation | 407 | 1,607* |
| Net cash from operating activities | (17,728) | (15,670)* |
| Purchases of property and equipment | 42 | 1,540* |
| Net cash from investing activities | (42) | (1,540)* |
| Net cash from financing activities | 39,908 | 138,575* |
| Net change in cash | 22,138 | 121,365* |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Mobia Medical | 177,090 | 13,505 | (15,670)* | 33.3M | 11.3 quarters | 10-QJun 30, 2026 |
| Venus Concept | 4,312 | 13,776 | (4,890)* | 1.9M | 0.9 quarters | 10-QSep 30, 2025 |
| Edap TMS | 21,542 | 13,203 | (3,691)* | 37.5M | 6.5 quarters | 10-QJun 30, 2026 |
| Apyx Medical | 27,617 | 13,884 | (3,490)* | 42.1M | 7.9 quarters | 10-QJun 30, 2026 |
| SS Innovations International | 13,647 | not reported | (4,235)* | 200.4M | 3.2 quarters | 10-QJun 30, 2026 |
| Iridex | 4,680 | 12,566 | 174* | 17.6M | — | 10-QJul 4, 2026 |
| LENSAR | 13,565 | 16,495 | (127)* | 12.3M | 106.8 quarters | 10-QJun 30, 2026 |
| ClearPoint Neuro | 46,184 | 12,075 | (20,100) | 32.1M | 6.6 quarters | 10-QSep 30, 2026 |
| KORU Medical Systems | 8,288 | 12,045 | 216* | 46.2M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.